Study: Aspirin Ineffective in 20 Percent of Heart Disease Patients

A major new study conducted in Ireland found that 20 percent of patients with established heart disease were not adequately protected by aspirin. Corgenix Medical Corporation, developers of the AspirinWorks^® Test for aspirin effect, said the study adds more evidence to the importance of accurately measuring aspirin response by measuring levels of the biomarker thromboxane.

"These and other major trials have established that the failure of patients to respond to the intended beneficial effect of aspirin may be a key factor in putting millions at increased risk of heart attack and stroke,” said Douglass Simpson, President and CEO of Corgenix (OTCBB:CONX). "The AspirinWorks Test accurately measures thromboxane levels in healthy individuals, allowing physicians to identify its potential interference with aspirin’s ability to help reduce heart attack and stroke risk.”

The Irish study conducted by the Irish Heart Foundation’s National Cardiovascular and Stroke Research Network (NCSRN) prospectively evaluated aspirin response in 700 patients with stable coronary artery disease by measuring thromboxane levels. Results showed that age, high blood pressure, weight and alcohol consumption were significant risk factors for a poor response to aspirin. Full study results were presented at the 64th Irish Cardiac Society Annual Scientific Meeting in Killarney, Ireland.

AspirinWorks is the only U.S. FDA-cleared test that measures the urinary biomarker 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect in apparently healthy individuals. The test identifies those individuals who have elevated thromboxane levels despite taking a daily aspirin dose, with studies showing up to 25 percent of individuals not seeing the expected beneficial effects of aspirin. AspirinWorks is used by thousands of physicians to test and guide treatment for hundreds of thousands of patients each year worldwide.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com.